Diagnostic Utility of Myeloperoxidase for Differentiating Irritable Bowel Syndrome From Inflammatory Bowel Disease in Patients With Lower GIT Symptoms
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 主要终点
- efficacy of myeloperoxidase for differentiating irritable bowel syndrome from inflammatory bowel disease.
研究概览
简要总结
The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome
详细描述
Myeloperoxidase is a lysosomal protein that is released from granules of neutrophil granulocytes during inflammation. the study design relies on the fact that there is no mucosal inflammation in case of functional gastrointestinal tract (GIT) disorders like irritable bowel syndrome (IBS), but organic gastrointestinal conditions like inflammatory bowel diseases (IBD) has mucosal inflammation and neutrophil influx into the mucosa.
the study is designed to assess myeloperoxidase levels in both conditions and assessing its reliability in differentiation between them.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.
- •Patients with no prior diagnosis of IBD or IBS.
- •Patients willing to provide informed consent and comply with study requirements.
- •Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels
排除标准
- •Patients with a confirmed diagnosis of IBD and currently on treatment.
- •Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.
- •Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.
- •Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.
- •Pregnant or lactating women.
结局指标
主要结局
efficacy of myeloperoxidase for differentiating irritable bowel syndrome from inflammatory bowel disease.
时间窗: baseline
Number of patients with elevated myeloperoxidase in irritable bowel syndrome and those with inflammatory bowel disease.
次要结局
未报告次要终点
研究者
Rania Mohammad Abd-ellatif
Internal medicine resident
Sohag University